Certara, a provider of model-informed drug development and decision support software, has announced the launch of BaseCase Data Manager, which allows clients to build interactive, data-driven mobile tools using real-world data sources, such as healthcare claims, costs, quality, outcomes, and population data.
Certara, a provider of global model-informed drug development software, has announced the launch of version 19.6 of D360, its scientific informatics platform for drug discovery and development. Designed to meet the scientific researcher’s need to quickly access, understand and share data, the D360 platform is delivered through its toolkits – small molecule discovery, biologics discovery, and pre-clinical translation – each tailored to meet specific research goals. This latest version of D360 takes its name from its release date; it is the 2019 mid-year release.
Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that it has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve worldwide equity in health. CGH is a new product development innovation practice inspired by Certara’s drug development and scientific due diligence work for the Bill & Melinda Gates Foundation.
Certara has announced the introduction of Certara Integral, its data repository for collecting, managing, and storing multiple types of data sets for analysis, sharing and reporting of clinical pharmacology, pharmacometrics and other relevant clinical data.
Certara, a provider of model-informed drug development, regulatory science, real-world evidence and market access services, has announced four senior executive appointments in its Simcyp division
Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360.
D360 v19.1 expands the platform’s capabilities for biologists and biologics scientists, deepens support for small molecule chemistry, and provides workflow enhancements based on community feedback. This latest version of D360 takes its name from its calendar release date; this is the first new release in 2019.
Certara, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 18 of its Simcyp Population-based Simulator
Certara has announced that Craig Rayner, PharmD, MBA, senior vice president, integrated drug development with Certara Strategic Consulting, has been awarded the 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
Certara has announced that the US Food and Drug Administration (FDA) has renewed, and in many cases increased, its number of Certara software licenses for reviewing new drug and biologics applications
Certara has announced that it has Pirana, a product for connecting and organising pharmacometric modelling results as well as providing interfaces to a range of software tools used in pharmacometrics modelling
The automotive sector is undergoing a period of rapid and disruptive transformation from both a business and technical standpoint.
Estimates suggest that the global laboratory informatics market, valued at $2.6 billion in 2019, will witness CAGR of 7.5 per cent over the next five years, reaching $3.8 billion in 2024[1].
Modern drug discovery and development workflows incorporate a growing range of automated, high-throughput technologies that can generate data on a truly impressive scale.
‘This will be the life sciences century … because of personalised medicine, information technology, and knowledge on biological systems,’ said Fred Hassan, a partner of Warburg Pincus and former CEO of Schering-Plough.
With data rates increasing and more complex challenges arising in life sciences, Panasas’ Jim Donovan and Dale Brantly discuss the benefits of using HPC for these workloads
As the complexity of both HPC hardware and the challenges that scientists are trying to solve using HPC systems increases, ensuring a system is utilised efficiently is necessary to deliver a computing service with value for money and a high research output.
Architectural specialisation is one option to continue to improve performance beyond the limits imposed by the slow down in Moore’s Law.
As not only the HPC industry but the larger computing ecosystem tries to overcome the slowdown and eventual end of transistor scaling described by Moore’s Law, scientists and researchers are implementing programmes that will define the technologies and new materials needed to supplement, or repla
